Vertex Pharmaceuticals VRTX Other — Total long-lived assets
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NoncurrentAssets.
The official record: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's other — total long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's other — total long-lived assets?
- Vertex Pharmaceuticals (VRTX) reported other — total long-lived assets of $27M in Q4 2025.
- How has Vertex Pharmaceuticals's other — total long-lived assets changed year-over-year?
- Vertex Pharmaceuticals's other — total long-lived assets increased by 73.1% year-over-year, from $15.6M to $27M.
- What does other — total long-lived assets mean?
- This metric measures the total book value of non-current, tangible, and intangible assets located in geographic regions outside of the company's primary domestic and home-country operations. It captures the physical and strategic infrastructure investments required to support commercial and operational activities in these specific international markets. Changes in this balance reflect the company's long-term capital commitment and asset deployment strategy in these regions.